These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 26708111

  • 1. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 2. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 3. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 Feb 07; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 4. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L, Nagy V, Vidal S, Czifrák K, Berzsényi E, Praly JP.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5680-3. PubMed ID: 18793852
    [Abstract] [Full Text] [Related]

  • 5. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase.
    Gimisis T.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1127-38. PubMed ID: 20716054
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 7. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

  • 9. Synthesis of C-xylopyranosyl- and xylopyranosylidene-spiro-heterocycles as potential inhibitors of glycogen phosphorylase.
    Somsák L, Bokor É, Czibere B, Czifrák K, Koppány C, Kulcsár L, Kun S, Szilágyi E, Tóth M, Docsa T, Gergely P.
    Carbohydr Res; 2014 Nov 18; 399():38-48. PubMed ID: 25081322
    [Abstract] [Full Text] [Related]

  • 10. Glucopyranosylidene-spiro-benzo[ b][1,4]oxazinones and -benzo[ b][1,4]thiazinones: Synthesis and Investigation of Their Effects on Glycogen Phosphorylase and Plant Growth Inhibition.
    Kun S, Kánya N, Galó N, Páhi A, Mándi A, Kurtán T, Makleit P, Veres S, Sipos Á, Docsa T, Somsák L.
    J Agric Food Chem; 2019 Jun 19; 67(24):6884-6891. PubMed ID: 31135156
    [Abstract] [Full Text] [Related]

  • 11. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).
    Donnier-Maréchal M, Vidal S.
    Expert Opin Ther Pat; 2016 Jun 19; 26(2):199-212. PubMed ID: 26666989
    [Abstract] [Full Text] [Related]

  • 12. Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.
    Docsa T, Czifrák K, Hüse C, Somsák L, Gergely P.
    Mol Med Rep; 2011 Jun 19; 4(3):477-81. PubMed ID: 21468595
    [Abstract] [Full Text] [Related]

  • 13. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 19; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 14. Insulin sensitivity is modified by a glycogen phosphorylase inhibitor: glucopyranosylidene-spiro-thiohydantoin in streptozotocin-induced diabetic rats.
    Docsa T, Marics B, Németh J, Hüse C, Somsák L, Gergely P, Peitl B.
    Curr Top Med Chem; 2015 Jun 19; 15(23):2390-4. PubMed ID: 26095241
    [Abstract] [Full Text] [Related]

  • 15. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 16. Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.
    Wang Y, Yan Z, Guo Y, Zhang L.
    Future Med Chem; 2021 May 01; 13(10):897-909. PubMed ID: 33906369
    [Abstract] [Full Text] [Related]

  • 17. Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.
    Kantsadi AL, Parmenopoulou V, Bakalov DN, Snelgrove L, Stravodimos GA, Chatzileontiadou DS, Manta S, Panagiotopoulou A, Hayes JM, Komiotis D, Leonidas DD.
    Curr Top Med Chem; 2015 May 01; 15(23):2373-89. PubMed ID: 26088352
    [Abstract] [Full Text] [Related]

  • 18. Exploring the Dual Inhibitory Activity of Novel Anthranilic Acid Derivatives towards α-Glucosidase and Glycogen Phosphorylase Antidiabetic Targets: Design, In Vitro Enzyme Assay, and Docking Studies.
    Ihmaid S.
    Molecules; 2018 May 29; 23(6):. PubMed ID: 29844263
    [Abstract] [Full Text] [Related]

  • 19. Glycogen phosphorylase inhibitors.
    Henke BR, Sparks SM.
    Mini Rev Med Chem; 2006 Aug 29; 6(8):845-57. PubMed ID: 16918491
    [Abstract] [Full Text] [Related]

  • 20. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E, Gregory L, Teague J, Myatt J, Hammond C, Poucher SM, Jones HB.
    Toxicol Pathol; 2010 Apr 29; 38(3):393-401. PubMed ID: 20215584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.